Read by QxMD icon Read

alopecia universalis

Poonam Verma, Surabhi Dayal, V K Jain, Ashish Amrani
Pegylated interferon α and ribavirin therapy is associated with increased incidence of various systemic and cutaneous side effects. Among the side effects of this therapy, alopecia universalis is a rarely reported side effect which causes significant cosmetic concern to the patient. We report a rare case of alopecia universalis which developed eight weeks after discontinuation of this antiviral combination therapy. This gains importance because it is essential to sensitize the treating gastroenterologist and the dermatologist regarding this rare side effect...
October 14, 2016: Journal of Chemotherapy
Ola Ahmed Bakry, Shawky M El Farargy, Maathir K El Shafiee, Amira Soliman
BACKGROUND: Alopecia areata (AA) is a common, recurrent, autoimmune hair disorder. It has been found that vitamin D deficiency is associated with many autoimmune diseases. AIMS: The current study aimed to estimate serum levels of 25-hydroxy vitamin D in patients with AA. MATERIALS AND METHODS: This case-control study included 60 patients with AA and 60 age, gender, skin phototype, and body mass index-matched healthy subjects as a control group...
September 2016: Indian Dermatology Online Journal
Milène Kennedy Crispin, Justin M Ko, Brittany G Craiglow, Shufeng Li, Gautam Shankar, Jennifer R Urban, James C Chen, Jane E Cerise, Ali Jabbari, Mårten C G Winge, M Peter Marinkovich, Angela M Christiano, Anthony E Oro, Brett A King
BACKGROUND: Alopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8(+) T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined. METHODS: This was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU)...
September 22, 2016: JCI Insight
Bérénice Dégboé, Félix Atadokpèdé, Bayaki Saka, Hugues Adégbidi, Christiane Koudoukpo, Hubert Yédomon, Florencia do Ango-Padonou
BACKGROUND: Vitiligo is unsightly on darkly pigmented skin and leads important stigmatization because of the mix-up with leprosy. PATIENTS AND METHODS: We analyzed retrospectively the epidemiological and clinical patterns of vitiligo on darkly pigmented skin between 1988 and 2008 in the Department of Dermatology in Cotonou (Benin). The diagnosis was made based on the clinical characteristics of vitiligo. RESULTS: Two hundred and forty-six patients were seen, representing 0...
September 28, 2016: International Journal of Dermatology
Catherine A Outerbridge, Stephen D White, Verena K Affolter
OBJECTIVE: To describe a case of testicular neoplasia and alopecia universalis in a dog, and successful treatment of the latter with ciclosporin. ANIMAL: Twelve-year-old intact male wirehaired fox terrier. METHODS: Castration, skin biopsy for histopathology, lymphocyte immunophenotyping and clonality analysis of the canine T-cell receptor gamma locus (TCRγ) rearrangement. RESULTS: The dog presented with symmetrical generalized alopecia...
September 19, 2016: Veterinary Dermatology
Sushma Malik, Mani Singhal, Shruti Sudhir Jadhav, Charusheela Sujit Korday, Chitra Shivanand Nayak
BACKGROUND: Hirschsprung's disease is one of the commonest causes of intestinal obstruction in neonates because of gut motility disorder. It is characterized as a complex genetic heterogenous disorder with variable inheritance. Hirschsprung's disease occurs as an isolated phenotype in majority (70 %) of cases. In other cases it may be associated with syndromes (such as Down's syndrome, Waardenburg syndrome, congenital central hypoventilation, or cartilage-hair hypoplasia) or with a spectrum of congenital anomalies involving neurological, cardiovascular, or urological systems or with sensorineural anomalies...
2016: Journal of Medical Case Reports
S Vañó-Galván, P Fernández-Crehuet, R Grimalt, M J Garcia-Hernandez, R Rodrigues-Barata, S Arias-Santiago, A Molina-Ruiz, E Garcia-Lora, J Dominguez-Cruz, A Brugues, J Ferrando, C Serrano-Falcón, S Serrano, J Paoli, F Camacho
BACKGROUND: Alopecia areata totalis (AAT) and universalis (AAU) pose a therapeutic challenge. OBJECTIVE: To describe the clinical and epidemiological features, therapeutic response and prognostic factors in a large series of patients diagnosed with AAT and AAU. METHODS: This retrospective multicenter study included patients diagnosed with AAT/AAU with a minimum follow-up of 12 months. Response was assessed based on the regrowth of scalp hair...
October 6, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
D Saceda-Corralo, R Grimalt, P Fernández-Crehuet, A Clemente, C Bernárdez, M J García-Hernandez, S Arias-Santiago, A R Rodrigues-Barata, A Rodríguez-Pichardo, E García-Lora, P Jaén, F M Camacho, S Vañó-Galván
BACKGROUND: Alopecia areata on the beard area (BAA) is a common clinical manifestation, but there are no studies about its characteristics. OBJECTIVE: To describe the epidemiology, comorbidities, clinical presentation, evolution, diagnostic findings and therapeutic choices in a series of patients with BAA. METHODS: This retrospective multicentre review included patients diagnosed with BAA as the first and unique clinical manifestation with at least 12 months of follow-up...
August 8, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
Ulrich Mrowietz, Sascha Gerdes, Regine Gläser, Oltmann Schröder
is missing (Short communication).
June 28, 2016: Acta Dermato-venereologica
Ali Jabbari, Jane E Cerise, James C Chen, Julian Mackay-Wiggan, Madeleine Duvic, Vera Price, Maria Hordinsky, David Norris, Raphael Clynes, Angela M Christiano
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects. Based on gene expression profiling, samples formed distinct clusters based on the presence or absence of disease as well as disease phenotype (patchy disease compared with alopecia totalis or universalis). Differential gene expression analysis allowed us to robustly demonstrate graded immune activity in samples of increasing phenotypic severity and generate a quantitative gene expression scoring system that classified samples based on interferon and cytotoxic T lymphocyte immune signatures critical for disease pathogenesis...
May 2016: EBioMedicine
A K Gupta, J L Carviel, W Abramovits
BACKGROUND: Autoimmune-triggered non-scarring hair loss is a feature of alopecia areata (AA). Initially patchy and often self-limited, severe hair loss forms include the complete loss of scalp hair or alopecia totalis (AT) and complete loss of all hair or alopecia universalis (AU). For AT and AU a reliable treatment has remained elusive. The targeted kinase inhibitor tofacitinib, in current use for treatment of other immune diseases, has been hypothesized as a viable option for AA, AT and AU therapy and a few case reports support this...
August 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
Ghada A Bin Saif
OBJECTIVES: To assess the significance of thyroid autoimmune screening in alopecia areata (AA) patients in Saudi population, and to determine whether there is a difference in thyroid autoimmune susceptibility between mild and severe AA. METHODS: In a prospective case-control study, we included 50 alopecia totalis (AT) and alopecia universalis (AU) patients, 50 age- and gender-matched patients with localized AA, and 50 age- and gender- matched healthy subjects between March 2015 and August 2015...
June 2016: Saudi Medical Journal
Florian Anzengruber, Julia-Tatjana Maul, Jivko Kamarachev, Ralph M Trüeb, Lars E French, Alexander A Navarini
Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia areata can be associated with a dramatic reduction of quality of life. Currently, no targeted treatment option is available, and topical immune therapies or immunosuppressive drugs are typically used with mixed success. Recently, several cases of alopecia areata responding to Janus kinase inhibitors were published...
January 2016: Case Reports in Dermatology
Yukiyasu Arakawa, Tomoko Nomiyama, Norito Katoh
Three hundred and eight nanometer excimer light therapy has recently been reported to be effective against patchy alopecia areata (AA) in several clinical studies. However, these studies only included a few patients with severe forms of AA, and all of them exhibited poor outcomes. We further investigated the use of excimer light as a therapeutic option for cases of alopecia universalis (AU) that are resistant to other treatments. Eleven treatment-resistant AU patients were treated with a 308-nm excimer light at 2-week intervals for more than 16 sessions...
April 30, 2016: Journal of Dermatology
Sergio Vañó-Galván, Ángela Hermosa-Gelbard, Natalia Sánchez-Neila, Laura Miguel-Gómez, David Saceda-Corralo, Rita Rodrigues-Barata, Pedro Jaén
No abstract text is available yet for this article.
May 2016: Journal of the American Academy of Dermatology
Sergio Vañó-Galván, Ángela Hermosa-Gelbard, Natalia Sánchez-Neila, Laura Miguel-Gómez, David Saceda-Corralo, Rita Rodrigues-Barata, Dong-Lai Ma, Pedro Jaén
No abstract text is available yet for this article.
May 2016: Journal of the American Academy of Dermatology
Oktay Esmer, Remzi Karadag, Ozgur Cakici, Serap Gunes Bilgili, Yuhanize Tas Demircan, Huseyin Bayramlar, Ayse S Karadag
OBJECTIVES: This study investigated ocular findings in patients with alopecia. METHODS: A total of 42 patients with alopecia (31 male, 11 female; 84 eyes) and 45 healthy individuals (28 male, 17 female; 90 eyes) were enrolled in the study. Of the patients with alopecia, 34 had alopecia areata, seven had alopecia universalis, and one had ophiasis alopecia. Seven patients had eyebrow involvement and seven had eyelash involvement. Autorefractometry, keratometry, visual acuity, central corneal thickness and intraocular pressure (IOP) measurements, bilateral anterior and posterior segment examinations, Schirmer's tests, and visual field examinations were performed in both groups...
July 2016: International Journal of Dermatology
Shivani Bansal, Naresh Kumar, Atul M Kochhar, Rajeev Ghai
No abstract text is available yet for this article.
January 2016: Indian Dermatology Online Journal
Mariya Miteva, Erin Wei, Clara Milikowski, Antonella Tosti
Alopecia in systemic amyloidosis is very rare and has been described as individual cases of diffuse nonscarring alopecia and a case of alopecia universalis. We report the trichoscopic findings in alopecia associated with systemic amyloidosis. The most prominent feature was a salmon colored halo (0.3-1 mm in diameter) surrounding the follicular ostia. Other features included broken hairs and black dots. The salmon colored halo correlated on pathology with the perifollicular deposition of amyloid. The horizontal sections showed that the sebaceous glands were preserved which supports the nonscarring pattern of the alopecia...
October 2015: International Journal of Trichology
María Ignacia Molina Molina, Carmen María Pinochet Paiva, José Ignacio Quezada Morales
Rheumatoid arthritis is a chronic, highly disabling autoimmune disease that requires aggressive pharmacological treatment using immunomodulatory drugs grouped under the name of Disease-Modifying Anti-rheumatic Drugs (DMARDs). Leflunomide is one of the most frequently prescribed. This drug, through its mechanism of action is able to suppress key factors in the disease process. However, its use is not without side effects. While there are series that report that the most prevalent adverse effects are diarrhea, nausea, rash and alopecia, there are few reported cases of alopecia universalis secondary to the use of leflunomide...
2015: Medwave
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"